BAYER AG
- Country
- ๐ฉ๐ชGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT05563454
- Locations
- ๐ฏ๐ต
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Japan
A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5000
- Registration Number
- NCT05552339
- Locations
- ๐ฉ๐ช
Many locations, Multiple Locations, Germany
An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in Europe
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 300
- Registration Number
- NCT05551039
- Locations
- ๐บ๐ธ
Many locations, Whippany, New Jersey, United States
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 354
- Registration Number
- NCT05537740
- Locations
- ๐ซ๐ท
Institut Gustave Roussy - Hematologie, Villejuif cedex, France
๐บ๐ธThe University of Chicago Medical Center (UCMC), Chicago, Illinois, United States
๐บ๐ธUniversity of North Carolina, Chapel Hill, North Carolina, United States
A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
- Conditions
- Interventions
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 22
- Registration Number
- NCT05532046
- Locations
- ๐ฎ๐น
Humanitas Research Hospital | Cardio Center - Clinical, Interventional Cardiology and Coronary Care, Milano, Lombardia, Italy
๐บ๐ธAccel Research Sites - Atlanta Clinical Research Center, Atlanta, Georgia, United States
๐บ๐ธWhite Oak Medical Center, Silver Spring, Maryland, United States
An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 50000
- Registration Number
- NCT05526157
- Locations
- ๐ช๐ธ
Many Locations, Multiple Locations, Spain
๐บ๐ธOptum CDM, Eden Prairie, Minnesota, United States
A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
- Conditions
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 65
- Registration Number
- NCT05526248
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธCentral Ohio Urology Group, Columbus, Ohio, United States
Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants
- Conditions
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 63
- Registration Number
- NCT05517746
- Locations
- ๐ฉ๐ช
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT05515432
- Locations
- ๐ฉ๐ช
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT05511038
- Locations
- ๐ฎ๐ณ
L.V. Prasad Eye Institute, Hyderabad, Andhra Pradesh, India
๐ฎ๐ณDisha Eye Hospitals, Kolkata, West Bengal, India
๐ฎ๐ณSankara Eye Hospital, Bengaluru, Karnataka, India